Exhibits serine-type endopeptidase activity. Involved in positive regulation of necroptotic process. Localizes to the early endosome. Orthologous to human GZMB (granzyme B); PARTICIPATES IN allograft rejection pathway; autoimmune thyroiditis pathway; graft-versus-host disease pathway; INTERACTS WITH (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; 1-chloro-2,4-dinitrobenzene; 17beta-estradiol.
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein]
[bisphenol A co-treated with Estradiol] results in increased expression of GZMB mRNA, [bisphenol A co-treated with Testosterone] results in increased expression of GZMB mRNA
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein], [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA, Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA]
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA, Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA]
2-tert-butylhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein], [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of GZMB protein
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA, Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of GZMB mRNA]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
